Canaccord analyst Tania Armstrong-Whitworth downgraded Knight Therapeutics (KHTRF) to Hold from Buy with a C$6.50 price target
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics Achieves Record Revenues and Expands Product Approvals
- Knight Therapeutics reports FY24 EPS C$0.04 vs. (C$0.16) last year
- Knight Therapeutics sees FY25 revenue C$390M-C$405M
- Knight Therapeutics (KHTRF) Q4 Earnings Cheat Sheet
- Knight Therapeutics price target raised to C$8 from C$7.50 at Raymond James